MAP2K7 and neoplasm: However, findings about combining MEK inhibitors with chemotherapeutic efficacy are controversial and probably depend on the tumor type and subtype; therefore, additional investigations should be performed to determine suitable combinations of MEK inhibitors with other chemotherapeutic and immunotherapeutic regimens for each candidate [61].